Interestingly, AZD6244 inhibited >75% DCIS.COM.ζ tumor growth but <50% DCIS.COM.Vec tumor growth, suggesting that the 14-3-3ζ overexpressing DCIS.COM.ζ tumors were more dependent on the MEK/ERK pathway and its downstream targets. Here, MAP2K7 is linked to ductal breast carcinoma in situ.